Idioma:

Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients

Buijsers, Baranca ; Yanginlar, Cansu ; Maciej-Hulme, Marissa L. ; de Mast, Quirijn ; van der Vlag, Johan

EBioMedicine, 2020-09, Vol.59, p.102969-102969, Article 102969 [Periódico revisado por pares]

Netherlands: Elsevier B.V

Texto completo disponível

Citações Citado por

Enviar para

Título:
Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients
Autor: Buijsers, Baranca ; Yanginlar, Cansu ; Maciej-Hulme, Marissa L. ; de Mast, Quirijn ; van der Vlag, Johan
Assuntos: Anti-Inflammatory Agents - metabolism ; Anti-Inflammatory Agents - pharmacology ; Anti-Inflammatory Agents - therapeutic use ; Betacoronavirus - isolation & purification ; Betacoronavirus - physiology ; Coronavirus Infections - drug therapy ; Coronavirus Infections - pathology ; Coronavirus Infections - virology ; COVID-19 ; Glucuronidase - antagonists & inhibitors ; Glucuronidase - metabolism ; Heparanase ; Heparin ; Heparin - metabolism ; Heparin - pharmacology ; Heparin - therapeutic use ; Heparin, Low-Molecular-Weight - metabolism ; Heparin, Low-Molecular-Weight - pharmacology ; Heparin, Low-Molecular-Weight - therapeutic use ; Histones - blood ; Histones - metabolism ; Humans ; Inflammation ; Low molecular weight heparin ; Pandemics ; Pneumonia, Viral - drug therapy ; Pneumonia, Viral - pathology ; Pneumonia, Viral - virology ; Review ; SARS-CoV-2 ; Virus Internalization - drug effects
É parte de: EBioMedicine, 2020-09, Vol.59, p.102969-102969, Article 102969
Notas: ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Equal contribution
Descrição: Coronavirus disease-2019 (COVID-19) is associated with severe inflammation in mainly the lung, and kidney. Reports suggest a beneficial effect of the use of heparin/low molecular weight heparin (LMWH) on mortality in COVID-19. In part, this beneficial effect could be explained by the anticoagulant properties of heparin/LMWH. Here, we summarise potential beneficial, non-anticoagulant mechanisms underlying treatment of COVID-19 patients with heparin/LMWH, which include: (i) Inhibition of heparanase activity, responsible for endothelial leakage; (ii) Neutralisation of chemokines, and cytokines; (iii) Interference with leukocyte trafficking; (iv) Reducing viral cellular entry, and (v) Neutralisation of extracellular cytotoxic histones. Considering the multiple inflammatory and pathogenic mechanisms targeted by heparin/LMWH, it is warranted to conduct clinical studies that evaluate therapeutic doses of heparin/LMWH in COVID-19 patients. In addition, identification of specific heparin-derived sequences that are functional in targeting non-anticoagulant mechanisms may have even higher therapeutic potential for COVID-19 patients, and patients suffering from other inflammatory diseases.
Editor: Netherlands: Elsevier B.V
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Resultado 1 Avançar Ir para próxima página

Realização: Logos de Redes Sociais:

Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients

Buijsers, Baranca ; Yanginlar, Cansu ; Maciej-Hulme, Marissa L. ; de Mast, Quirijn ; van der Vlag, Johan

Netherlands: Elsevier B.V

Buscando em bases de dados remotas. Favor aguardar.